Tuesday, October 23 - Wednesday, October 24
Washington, D.C.
October 02, 2018
Posters for VenatoRx's lead clinical antibacterial candidate, cefepime/VNRX-5133, will be presented on Friday, October 5, 2018 in S Poster Hall from 12:30pm to 1:45pm PT.
September 25, 2018
VenatoRx entered into an exclusive license agreement with Everest Medicines II Limited, a C-Bridge Capital-backed biopharmaceutical company with operations based in China, to support the development, registration and commercialization of cefepime/VNRX-5133 in Greater China, South Korea and Southeast Asia for complicated urinary tract infections (cUTI), infections due to carbapenem resistant pathogens, and hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).
September 04, 2018
SMi Group is proud to announce the return of the Superbugs & Superdrugs USA conference to Iselin, NJ on the 12th and 13th November 2018.
August 09, 2018
VenatoRx was named one of the “2018 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal. Founded in 2010, VenatoRx has grown from three founders to over 50 employees who are heavily comprised of entrepreneurial-minded scientists and operators who have had career success in big pharma and start-up environments.
May 31, 2018
VenatoRx's lead clinical antibacterial candidate, cefepime/VNRX-5133, will be featured in the New Agents Discovery Summary Session: Early New Antimicrobial Agents; Emerging Tech Talks; and five poster presentations on June 8-9, 2018 in Atlanta, GA.
May 17, 2018
President and CEO, Christopher J. Burns, Ph.D., will present attendees with an overview of VenatoRx’s pipeline and its unique operating model of leveraging non-dilutive funding to maximize investor dollars on Monday, 21, 2018 at 8:00am ET in Ballroom V at the Grand Hyatt New York.
April 19, 2018
The awards program recognizes entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities. Drs. Burns, Xerri and Pevear were selected as finalists by a panel of independent judges. Award winners will be announced at a special gala event on June 14, 2018 at the Kimmel Center for the Performing Arts.
April 12, 2018
Fourteen poster presentations, including four oral sessions, will feature VenatoRx's lead clinical antibacterial candidate, cefepime/VNRX-5133, at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain. In addition, VenatoRx’s President and CEO, Christopher J. Burns, Ph.D., will present a brief overview about the Company’s R&D pipeline during Pipeline Corner on April 23, 2013 beginning at 12:30pm CET in Hall Y.